Compare Heron Therapeutics Inc (HRTX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Charles Schwab Corporation Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Charles Schwab Corporation Common Stock trades at $97 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 2463.2× Heron Therapeutics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| HRTX | SCHW | |
|---|---|---|
Market Cap | $68.01M | $167.52B |
Volume | 1,891,941 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $1.49 | $113.65 |
52-Week Low | $0.27 | $85.35 |
Typical Hold Time | 35 Days | 85 Days |
Enterprise Value | $174.75M | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Charles Schwab (SCHW) trades at $95.58, down 1.26% today, with a bearish technical signal. The stock shows strong fundamentals, with Q2 2026 EPS beating expectations at $1.62 and revenue growth to $23.92B in 2025. Analyst consensus is bullish, with a $119.92 price target, supported by recent news of a secondary listing on the Texas Stock Exchange and AI integration for advisors.
Outlook remains positive due to earnings momentum and market share gains, but risks include competitive pressures and interest rate sensitivity. The stock offers upside from current levels if execution continues, though technical weakness may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
